Replies to post #95259 on Cytodyn Inc (CYDY)

[bobshmob]

Hear, hear! A perfecta for leronlimab, m/m now and in a week or two DSMB intervenes to cut short the s/c trials to give leronlimab to the placebo arm to save lives.

[Saltz]

That is precisely what we want to see happen. It would seem that the midpoint in enrollment would be the timeline for such a decision. I’m suspecting we are at 150 enrolled and 195 patients would be the half way point.

Can’t imagine being one of the very sick that is on placebo. It’s unconscionable.

[Borel Fields]

I'm listening to the arguments as to why the m/m or s/c trial is more likely to be statistically significant. But is "significant" all there is to "important?"

I've been seeing another figure of merit: how many patients do you have to treat to save one life? Clearly, that metric favors using the (presumably limited) doses of leronlimab in the s/c setting, where death is otherwise imminent for a substantial fraction of patients, even though a few patients might be unsalvageable.

For the m/m benefit calc, there would need to be some estimate of what fraction of patients "saved" by leronlimab (from progressing to s/c) would have eventually died.